AU5564690A - Creation of Inventions and Patents with Artificial Intelligence

AU5564690A – Fusion proteins containing n-terminal fragments of human serum albumin
– Google Patents

AU5564690A – Fusion proteins containing n-terminal fragments of human serum albumin
– Google Patents
Fusion proteins containing n-terminal fragments of human serum albumin

Info

Publication number
AU5564690A

AU5564690A
AU55646/90A
AU5564690A
AU5564690A
AU 5564690 A
AU5564690 A
AU 5564690A
AU 55646/90 A
AU55646/90 A
AU 55646/90A
AU 5564690 A
AU5564690 A
AU 5564690A
AU 5564690 A
AU5564690 A
AU 5564690A
Authority
AU
Australia
Prior art keywords
hsa
variant
terminal
fusion polypeptide
sequence
Prior art date
1989-04-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU55646/90A
Other versions

AU630450B2
(en

Inventor
David James Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novozymes Biopharma UK Ltd

Original Assignee
Novozymes Biopharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1989-04-29
Filing date
1990-04-26
Publication date
1990-11-29

1990-04-26
Application filed by Novozymes Biopharma UK Ltd
filed
Critical
Novozymes Biopharma UK Ltd

1990-11-29
Publication of AU5564690A
publication
Critical
patent/AU5564690A/en

1992-10-29
Application granted
granted
Critical

1992-10-29
Publication of AU630450B2
publication
Critical
patent/AU630450B2/en

2006-12-21
Assigned to NOVOZYMES DELTA LIMITED
reassignment
NOVOZYMES DELTA LIMITED
Request to Amend Deed and Register
Assignors: DELTA BIOTECHNOLOGY LIMITED

2010-01-21
Assigned to NOVOZYMES BIOPHARMA UK LIMITED
reassignment
NOVOZYMES BIOPHARMA UK LIMITED
Request to Amend Deed and Register
Assignors: NOVOZYMES DELTA LIMITED

2010-04-26
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts

C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi

C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/76—Albumins

C07K14/765—Serum albumin, e.g. HSA

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K19/00—Hybrid peptides

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

C12N15/62—DNA sequences coding for fusion proteins

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C07K2319/50—Fusion polypeptide containing protease site

Description

Fusion proteins containing N-terminal fragments of human serum albumin
The present invention relates to fusion polypeptides where two individual polypeptides or parts thereof are fused to form a single amino acid chain. Such fusion may arise from the expression of a single continuous coding sequence formed by recombinant DNA techniques.
Fusion polypeptides are known, for example those where a polypeptide which is the ultimately desired product of the process is expressed with an N-terminal “leader sequence” which encourages or allows secretion of the polypeptide from the cell. An example is disclosed in EP-A-116 201 (Chiron) .
Human serum albumin (HSA) is a known protein found in the blood. EP-A-147 198 (Delta Biotechnology) discloses its expression in a transformed host, in this case yeast. Our earlier application EP-A-322 094 discloses N-terminal fragments of HSA, namely those consisting of residues 1-n where n is 369 to 419, which have therapeutic utility. The application also mentions the possibility of fusing the C-terminal residue of such molecules to other, unnamed, polypeptides.

One aspect of the present invention provides a fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N- terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is (a) the 585 to 1578 portion of human fibronectin or a variant thereof, (b) the 1 to 368 portion of CD4 or a variant thereof, (c) platelet derived growth factor, or a variant thereof, (d) transforming growth factor, or a variant thereof, (e) the 1-261 portion of mature human plasma fibronectin or a variant thereof, (f) the 278-578 portion of mature human plasma fibronectin or a variant thereof, (g) the 1-272 portion of mature human von illebrand’s Factor or a variant thereof, or (h) alpha-1-antitrypsin or a variant thereof.
The N-terminal portion of HSA is preferably the said 1-n portion, the 1-177 portion (up to and including the cysteine), the 1-200 portion (up to but excluding the cysteine) or a portion intermediate 1-177 and 1-200.

The term “human serum albumin” (HSA) is intended to include (but not necessarily to be restricted to) known or yet-to-be-discovered polymorphic forms of HSA. For example, albumin Naskapi has Lys-372 in place of Glu-372 and pro-albumin Christchurch has an altered pro-sequence. The term “variants” is intended to include (but not necessarily to be restricted to) minor artificial variations in sequence (such as molecules lacking one or a few residues, having conservative substitutions or minor insertions of residues, or having minor variations of amino acid structure). Thus polypeptides which have 80%, preferably 85%, 90%, 95% or 99%, homology with HSA are deemed to be “variants”. It is also preferred for such variants to be physiologically equivalent to HSA; that is to say, variants preferably share at least one pharmacological utility with HSA. Furthermore, any putative variant which is to be used pharmacologically should be non-immunogenic in the animal (especially human) being treated.
Conservative substitutions are those where one or more amino acids are substituted for others having similar properties such that one skilled in the art of polypeptide chemistry would expect at least the secondary structure, and preferably the tertiary structure, of the polypeptide to be substantially unchanged. For example, typical such

substitutions include asparagine for glutamine, serine for asparagine and arginine for lysine. Variants may alternatively, or as well, lack up to ten (preferably only one or two) intermediate amino acid residues (ie not at the termini of the said N-terminal portion of HSA) in comparison with the corresponding portion of natural HSA; preferably any such omissions occur in the 100 to 369 portion of the molecule (relative to mature HSA itself) (if present). Similarly, up to ten, but preferably only one or two, amino acids may be added, again in the 100 to 369 portion for preference (if present). The term “physiologically functional equivalents” also encompasses larger molecules comprising the said sequence plus a further sequence at the N-terminal (for example, pro-HSA, pre-pro-HSA and met-HSA) .
Clearly, the said “another polypeptide” in the fusion compounds of the invention cannot be the remaining portion of HSA, since otherwise the -whole polypeptide would be HSA, which would not then be a “fusion polypeptide”.
Even when the HSA-like portion is not the said 1-n portion of HSA, it is preferred for the non-HSA portion to be one of the said (a) to (h) entities.

The 1 to 368 portion of CD4 represents the first four disulphide-linked immunoglobulin-like domains of the human T lymphocyte CD4 protein, the gene for and amino acid sequence of which are disclosed in D. Smith et al (1987) Science 328, 1704-1707. It is used to combat HIV infections.
The sequence of human platelet-derived growth factor (PDGF) is described in Collins et al_ (1985) Nature 316, 748-750. Similarly, the sequence of transforming growth factors β (TGF-β) is described in Derynck et al (1985) Nature 316, 701-705. These growth factors are useful for wound-healing.
A cDNA sequence for the 1-261 portion of Fn was disclosed in EP-A-207 751 (obtained from plasmid pFH6 with endonuclease PvuII). This portion binds fibrin and can be used to direct fused compounds to blood clots.
A cDNA sequence for the 278-578 portion of Fn, which contains a coilagen-binding domain, was disclosed by R.J. Owens and F.E. Baralle in 1986 E. .B.O.J. 5_, 2825-2830. This portion will bind to platelets.

The 1-272 portion of von illebrand’s Factor binds and stabilises factor VIII. The sequence is given in Bontha et al, Nucl. Acids Res. 1Λ_, 7125-7127.
Variants of alpha-1-antitrypsin include those disclosed by Rosenburg et al (1984) Nature 312, 77-80. In particular, the present invention includes the Pittsburgh variant (Met^5^ is mutated to Arg) and the variant where ro-^57 and

are mutated to alanine and arginine respectively. These compounds are useful in the treatment of septic shock and lung disorders.
Variants of the non-HSA portion of the polypeptides of the invention include variations as discussed above in relation to the HSA portion, including those with conservative amino acid substitutions, and also homologues from other species.
The fusion polypeptides of the invention may have N- ter inal amino acids which extend beyond the portion corresponding to the N-terminal portion of HSA. For example, if the HSA-like portion corresponds to an N- ter inal portion of mature HSA, then pre-, pro-, or pre- pro sequences may be added thereto, for example the yeast alpha-factor leader sequence. The fused leader portions of WO 90/01063 may be used. The polypeptide which is

fused to the HSA portion may be a naturally-occurring polypeptide, a fragment thereof or a novel polypeptide, including a fusion polypeptide. For example, in Example 3 below, a fragment of fibronectin is fused to the HSA portion via a 4 amino acid linker.
It has been found that the amino terminal portion of the HSA molecule is so structured as to favour particularly efficient translocation and export of the fusion compounds of the invention in eukaryotic cells.
A second aspect of the invention provides a • transformed host having a nucleotide sequence so arranged as to express a fusion polypeptide as described above. By “so arranged”, we mean, for example, that the nucleotide sequence is in correct reading frame with an appropriate RNA polymerase binding site and translation start sequence and is under the control of a suitable promoter. The promoter may be homologous with or heterologous to the host. Downstream (3′) regulatory sequences may be included if desired, as is known. The host is preferably yeast (for example Saccharomyces spp. , e.g. S. cerevisiae; Kluyveromyces spp., e.g. K. lactis; Pichia spp.; or Schizosaccharomyces spp., e.g. S. pombe) but may be any

other suitable host such as E. coli, B. subtilis, Asperqillus spp., mammalian cells, plant cells or insect cells.
A third aspect of the invention provides a process for preparing a fusion polypeptide according to the first aspect of the invention by cultivation of a transformed host according to the second aspect of the invention, followed by separation of the fusion polypeptide in a useful form.
A fourth aspect of the invention provides therapeutic methods of treatment of the human or other animal body comprising administration of such a fusion polypeptide.
In the methods of the invention we are particularly concerned to improve the efficiency of secretion of useful therapeutic human proteins from yeast and have conceived the idea of fusing to amino-terminal portions of HSA those proteins which may ordinarily be only inefficiently secreted. One such protein is a potentially valuable wound-healing polypeptide representing amino acids 585 to 1578 of human fibronectin (referred to herein as Fn 585- 1578). As we have described in a separate application (filed simultaneously herewith) this molecule contains cell spreading, chemotactic and chemokinetic activities

useful in healing wounds. The fusion polypeptides of the present invention wherein the C-terminal portion is Fn 585-1578 can be used for wound healing applications as biosynthesised, especially where the hybrid human protein will be topically applied. However, the portion representing amino acids 585 to 1578 of human fibronectin can if desired be recovered from the fusion protein by preceding the first amino acid of the fibronectin portion by amino acids comprising a factor X cleavage site. After isolation of the fusion protein from culture supernatant, the desired molecule is released by factor X cleavage and purified by suitable chromatography (e.g. ion-exchange chromatography) . Other sites providing for enzymatic or chemical cleavage can be provided, either by appropriate juxtaposition of the N-terminal and C-terminal portions or by the insertion therebetween of an appropriate linker.
At least some of the fusion polypeptides of the invention, especially those including the said CD4 and vWF fragments, PDGF and AT, also have an increased half-life in the blood and therefore have advantages and therapeutic utilities themselves, namely the therapeutic utility of the non-HSA portion of the molecule. In the case of ^AT and others, the compound will normally be administered as

a one-off dose or only a few doses over a short period, rather than over a long period, and therefore the compounds are less likely to cause an immune response.
EXAMPLES : SUMMARY
Standard recombinant DNA procedures were as described by Maniatis et al (1982 and recent 2nd edition) unless otherwise stated. Construction and analysis of phage M13 recombinant clones was as described by Messing (1983) and Sanger et al (1977).
DNA sequences encoding portions of human serum albumin used in the construction of the following molecules are derived from the plas ids mH0B12 and pDBD2 (EP-A-322 094, Delta Biotechnology Ltd, relevant portions of which are reproduced below) or by synthesis of oligonucleotides equivalent to parts of this sequence. DNA sequences encoding portions of human fibronectin are derived from the plasmid pFHDELl, or by synthesis of oligonucleotides equivalent to parts of this sequence. Plasmid pFHDELl, which contains the complete human cDNA encoding plasma fibronectin, was obtained by ligation of DNA derived from plasmids pFH6, 16, 54, 154 and 1 (EP-A-207 751; Delta Biotechnology Ltd) .

This DNA represents an mRNA variant which does not contain the ‘ED’ sequence and had an 89-amino acid variant of the III-CS region (R.J. Owens, A.R. Kornblihtt and F.E. Baralle (1986) Oxford Surveys on Eukaryotic Genes _3 141- 160). The map of this vector is disclosed in Fig. 11 and the protein sequence of the mature polypeptide produced by expression of this cDNA is shown in Fig. 5.
Oligonucleotides were synthesised on an Applied Biosystems 380B oligonucleotide synthesiser according to the manufacturer’s recommendations (Applied Biosystems, Warrington, Cheshire, UK).
An expression vector was constructed in which DNA encoding’ the HSA secretion signal and mature HSA up to and including the 387th amino acid, leucine, fused in frame to DNA encoding a segment of human fibronectin representing amino acids 585 to 1578 inclusive, was placed downstream of the hybrid promoter of EP-A-258 067 (Delta Biotechnology) , which is a highly efficient galactose- inducible promoter functional in Saccharomyces cerevisiae. The codon for the 1578th amino acid of human fibronectin was directly followed by a stop codon (TAA) and then the S. cerevisiae phosphoglycerate kinase (PGK) gene transcription terminator. This vector was then introduced into S. cerevisiae by transformation, wherein it directed

the expression and secretion from the cells of a hybrid molecule representing the N-terminal 387 amino acids of HSA C-terminally fused to amino acids 585 to 1578 of human fibronectin.
In a second example a similar vector is constructed so as to enable secretion by S. cerevisiae of a hybrid molecule representing the N-terminal 195 amino acids of HSA C- terminally fused to amino acids 585 to 1578 of human fibronectin.
Aspects of the present invention will now be described by way of example and with reference to the accompanying drawings, in which:
Figure 1 (on two sheets) depicts the amino acid sequence currently thought to be the most representative of natural HSA, with (boxed) the alternative C-termini of HSA(l-n);
Figure 2 (on two sheets) depicts the DNA sequence coding for mature HSA, wherein the sequence included in Linker 3 is underlined;
Figure 3 illustrates, diagrammatically, the construction of mH0B16;

Figure 4 illustrates, diagrammatically, the construction of pH0B31;
Figure 5 (on 6 sheets) illustrates the mature protein sequence encoded by the Fn plasmid pFHDELl;
Figure 6 illustrates Linker 5, showing the eight constituent oligonucleotides;
Figure 7 shows schematically the construction of plasmid pDBDF2;
Figure 8 shows schematically the construction of plasmid pDBDF5;
Figure 9 shows schematically the construction of plasmid pDBDF9;
Figure 10 shows schematically the construction of plasmid DBDF12, using plasmid pFHDELl; and
Figure 11 shows a map of plasmid pFHDELl.

EXAMPLE 1 ; HSA 1-387 FUSED TO Fn 585-1578
The following is an account of a preparation of plasmids comprising sequences encoding a portion of HSA, as is disclosed in EP-A-322 094.
The human serum albumin coding sequence used in the construction of the following molecules is derived from the plasmid M13mpl9.7 (EP-A-201 239, Delta Biotech- nology Ltd. ) or by synthesis of oligonucleotides equivalent to parts of this sequence. Oligonucleotides were synthesised using phosphoramidite chemistry on an Applied Biosystems 380B oligonucleotide synthesizer according to the manufacturer’s recommendations (AB Inc., Warrington, Cheshire, England) .
An oligonucleotide was synthesised (Linker A) which represented a part of the known HSA coding sequence (Figure 2) from the PstI site (1235-1240, Figure 2) to the codon for valine 381 wherein that codon was changed from GTG to GTC:

Linker 1
D P H E C Y
5′ GAT CCT CAT GAA TGC TAT
3′ ACGT CTA GGA GTA CTT ACG ATA
1247
A K V F D E F K
GCC AA GTG TTC GAT GAA TTT AAA
CGG TT CAC AAG CTA CTT AAA TT 1267
P L V
CTT GTC 3′
GGA CAG 5′
Linker 1 was ligated into the vector M13mpl9 (Norrander et al, 1983) which had been digested with PstI and Hindi and the ligation mixture was used to transfect E.coli strain XLl-Blue (Stratagene Cloning Systems, San Diego, CA) . Recombinant clones were identified by their failure to evolve a blue colour on medium containing the chromogenic indicator X-gal (5-bromo-4-chloro-3-indolyl-β- D-galactoside) in the present of IPTG (isopropylthio-β- galactoside) . DNA sequence analysis of template DNA prepared from bacteriophage particles of recombinant clones identified a molecule with the required DNA sequence, designated mH0B12 (Figure 3).

M13mpl9.7 consists of the coding region of mature HSA in M13mpl9 (Norrander et al, 1983) such that the codon for the first amino acid of HSA, GAT, overlaps a unique Xhol site thus:
Asp Ala 5′ C T C G A G A G C A 3′ 3′ G A G C T C T A C G T 5′ Xhol
(EP-A-210 239). M13mpl9.7 was digested with Xhol and made flush-ended by Sl-nuclease treatment and was then ligated with the following oligonucleotide (Linker 2):
Linker 2
5′ T C T T T T A T C C A A G C T T G G A T A A A A G A 3′ 3′ A G A A A A T A G G T T C G A A C C T A T T T T C T 5′
HindIIT
The ligation mix was then used to transfect E.coli XL1- Blue and template DNA was prepared from several plaques and then analysed by DNA sequencing to identify a clone, pDBDl (Figure 4), with the correct sequence.

A 1.1 kb HindiII to PstI fragment representing the 5′ end of the HSA coding region and one half of the inserted oligonucleotide linker was isolated from pDBDl by agarose gel electrophoresis. This fragment was then ligated with double stranded mHOB12 previously digested with HindiII and PstI and the ligation mix was then used to transfect E.coli XLl-Blue. Single stranded template DNA was prepared from mature bacteriophage particles of several plaques. The DNA was made double stranded in vitro by extension from annealed sequencing primer with the Klenow fragment of DNA polymerase I in the presence of deoxynucleoside triphosphates. Restriction enzyme analysis of this DNA permitted the identification of a clone with the correct configuration, mHOB15 (Figure 4).
The following oligonucleotide (Linker 3) represents from the codon for the 382nd amino acid of mature HSA (glutamate, GAA) to the codon for lysine 389 which is followed by a stop codon (TAA) and a HindiII site and then a BamHI cohesive end:
Linker 3
E E P Q N L I K J 5′ GAA GAG CCT CAG AAT TTA ATC AAA TAA GCTTG 3′ 3′ CTT CTC GGA GTC TTA AAT TAG TTT ATT CGAACCTAG 5′

This was ligated into double stranded mHOB15, previously digested with Hindi and BamHI. After ligation, the DNA was digested with Hindi to destroy all non-recombinant molecules and then used to transfect E.coli XLl-Blue. Single stranded DNA was prepared from bacteriophage particles of a number of clones and subjected to DNA sequence analysis. One clone having the correct DNA sequence was designated mH0B16 (Figure 4).
A molecule in which the mature HSA coding region was fused to the HSA secretion signal was created by insertion of Linker 4 into BamHI and Xhol digested M13mpl9.7 to form pDBD2 (Figure 4).
Linker 4
M K W V S F
5′ GATCC ATG AAG TGG GTA AGC TT
G TAC TTC ACC CAT TCG AAA
—
I S L L F L F S
ATT TCC CTΪ 1 CTT TTT CTC TT AG(
TAA AGG GAA GAA AAA GAG AAA TC(

S A Y S R G V F
TCG GCT TAT TCC AGG GGT GTG TT
AGC CGA ATA AGG CC CCA CAC AAA
R R
CG 3′
GCAGCT 5′
In this linker the codon for the fourth amino acid after the initial methionine, ACC for threonine in the HSA pre- pro leader sequence (Lawn et al, 1981), has been changed to AGC for serine to create a Hindlll site.
A sequence of synthetic DNA representing a part of the known HSA coding sequence (Lawn et al. , 1981) (amino acids
382 to 387, Fig. 2), fused to part of the known fibronectin coding sequence (Kornblihtt et al. , .1985)
(amino acids 585 to 640, Fig. 2), was prepared by synthesising six oligonucleotides (Linker 5, Fig. 6). The oligonucleotides 2, 3, 4, 6, 7 and 8 were phosphorylated using T4 polynucleotide kinase and then the oligonucleotides were annealed under standard conditions in pairs, i.e. 1+8, 2+7, 3+6 and 4+5. The annealed oligonucleotides were then mixed together and ligated with mHOB12 which had previously been digested with the restriction enzymes Hindi and EcoRI. The ligation

mixture was then used to transfect E.coli XLl-Blue (Stratagene Cloning Systems, San Diego, CA) . Single stranded template DNA was then prepared from mature bacteriophage particles derived from several independent plaques and then was analysed by DNA sequencing. A clone in which a linker of the expected sequence had been correctly inserted into the vector was designated pDBDFl (Fig. 7). This plasmid was then digested with PstI and EcoRI and -the approx. 0-24kb fragment was purified and then ligated with the 1.29kb BamHI-PstI fragment of pDBD2 (Fig. 7) and BamHI + EcoRI digested pUC19 (Yanisch-Perron, et al. , 1985) to form pDBDF2 (Fig. 7).
A plasmid containing a DNA sequence encoding full length human fibronectin, pFHDELl, was digested with EcoRI and Xhol and a 0.77kb EcoRI-XhoI fragment (Fig. 8) was isolated and then ligated with EcoRI and Sail digested Ml3 mplδ (Norrander et al., 1983) to form pDBDF3 (Fig. 8).
The following oligonucleotide linker (Linker 6) was synthesised, representing from the PstI site at 4784-4791 of the fibronectin sequence of EP-A-207 751 to the codon for tyrosine 1578 (Fig. 5) which is followed by a stop codon (TAA) , a HindiII site and then a BamHI cohesive end:

Linker 6
G P D Q T E M T I E G L GGT CCA GAT CAA ACA GAA ATG ACT ATT GAA GGC TTG A CGT CCA GGT CTA GTT TGT CTT TAC TGA TAA CTT CCG AAC
Q P T V E Y Stop CAG CCC ACA GTG GAG TAT TAA GCTTG GTC GGG TGT CAC CTC ATA ATT CGAACCTAG
This linker was then ligated with PstI and HinduI digested pDBDF3 to form pDBDF4 (Fig. 8).. The following DNA fragments were then ligated together with Bqlll digested pKV50 (EP-A-258 067) as shown in Fig. 8: 0.68kb EcoRI-BamHI fragment of pDBDF4, 1.5kb BamHI-StuI fragment of pDBDF2 and the 2.2kb StuI-EcoRI fragment of pFHDELl. The resultant plasmid pDBDF5 (Fig. 8) includes the promoter of EP-A-258 067 to direct the expression of the HSA secretion signal fused to DNA encoding amino acids 1- 387 of mature HSA, in turn fused directly and in frame with DNA encoding amino acids 585-1578 of human fibronectin, after which translation would terminate at the stop codon TAA. This .is then followed by the S.cerevisiae PGK gene transcription terminator. The

plasmid also contains sequences which permit selection and maintenance in Escherichia coli and S.cerevisiae (EP-A-258 067) .
This plasmid was introduced into S.cerevisiae S150-2B (leu2-3 leu2-112 ura3-52 trpl-289 his3- 1) by standard procedures (Beggε, 1978). Transformants were subsequently analysed and found to produce the HSA-fibronectin fusion protein.
EXAMPLE 2 : HSA 1-195 FUSED TO Fn 585-1578
In this second example the first domain of human serum albumin (amino acids 1-195) is fused to amino acids 585- 1578 of human fibronectin.
The plasmid pDBD2 was digested with BamHI and Bglll and the 0.79kb fragment was purified and then ligated with BamHI-digested M13mpl9 to fo’rm pDBDF6 (Fig. 6). The following oligonucleotide:
5′-C C A AA G C T C G A G G A A C T T C G-3′
was used as a mutagenic primer to create a Xhol site in pDBDF6 by in vitro mutagenesis using a kit supplied by Amersham International PLC. This site was created by

changing base number 696 of HSA from a T to a G (Fig. 2). The plasmid thus formed was designated pDBDF7 (Fig. 9). The following linker was then synthesised to represent from this newly created Xhol site to the codon for lysine 195 of HSA (AAA) and then from the codon for isoleucine 585 of fibronectin to the ends of oligonucleotides 1 and 8 shown in Fig. 6.
Linker 7
D E L R D E G K A S. S A K TC GAT GAA CTT CGG GAT GAA GGG AAG GCT TCG TCT GCC AAA A CTT GAA GCC CTA CTT CCC TTC CGA AGC AGA CGG TTT
I T E T P S Q P N S H ATC ACT GAG ACT CCG AGT CAG C TAG TGA CTC TGA GGC TCA GTC GGG TTG AGG GTG G
This linker was ligated with the annealed oligonucleotides shown in Fig. 3, i.e. 2+7, 3+6 and 4+5 together with Xhol and EcoRI digested pDBDF7 to form pDBDFδ (Fig. 9). Note that in order to recreate the original HSA DNA sequence, and hence amino acid sequence, insertion of linker 7 and the other oligonucleotides into pDBDF7 does not recreate the Xhol site.

The 0.83kb BamHI-StuI fragment of pDBDF8 was purified and then was ligated with the 0.68kb EcoRI-BamHI fragment of pDBDF2 and the 2.22kb StuI-EcoRI fragment of pFHDELl into Bglll-digested pKV50 to form pDBDF9 (Fig. 9). This plasmid is similar to pDBDF5 except that it specifies only residues 1-195 of HSA rather than 1-387 as in pDBDF5.
When introduced into S.cerevisiae S150-2B as above, the plasmid directed the expression and secretion of a hybrid molecule composed of residues 1-195 of HSA fused to residues 585-1578 of fibronectin.
EXAMPLE 3 : HSA 1-387 FUSED TO Fn 585-1578, AS CLEAVABLE MOLECULE
In order to facilitate production of large amounts of residues 585-1578 of fibronectin, a construct was made in which DNA encoding residues 1-387 of HSA was separated from DNA encoding residues 585-1578 of fibronectin by the sequence
I E G R ATT GAA GGT AGA TAA CTT CCA TCT

which specifies the cleavage recognition site for the blood clotting Factor X. Consequently the purified secreted product can be treated with Factor X and then the fibronectin part of the molecule can be separated from the HSA part.
To do this two oligonucleotides were synthesised and then annealed to form Linker 8.
Linker 8
E E P Q N L – I E 6 ” GAA GAG CCT CAG AAT TTA ATT GAA GGT CTT CTC GGA GTC TTA AAT TAA CTT CCA
R I T E T P S Q P AGA ATC ACT GAG ACT CCG AGT CAG C TCT TAG TGA CTC TGA GGC TCA GTC GGG
N S H
TTG AGG GTG G
This linker was then ligated with the annealed oligonucleotides shown in Fig. 6, i.e. 2+7, 3+6 and 4+5 into Hin i andEcoRI digested mH0B12, to form pDBDFlO

(Fig. 7). The plasmid was then digested with PstI and EcoRI and the roughly 0.24kb fragment was purified and then ligated with the 1.29kb BamHI-PstI fragment of pDBD2 and BamHI and EcoRI digested pUC19 to form pDBDFll (Fig. 10) .
The 1.5kb BamHI-StuI fragment of pDBDFll was then ligated with the 0.68kb EcoRI-BamHI fragment of pDBDF4 and the 2.22kb StuI-EcoRI fragment of pFHDELl into Bglll-diges ed pKV50 to form pDBDF12 (Fig. 10). This plasmid was then introduced into S.cerevisiae S150-2B. The purified secreted fusion protein was treated with Factor X to liberate the fibronectin fragment representing residues 585-1578 of the native molecule.

REFERENCES
Beggs, J.D. (1978) Nature 2J7j>, 104-109
Kornblihtt et al. (1985) EMBO J. , 1755-1759
Lawn, R.M. et al. (1981) Nucl. Acid. Res. 9_, 6103-6114
Maniatis, T. et al. (1982) Molecular cloning: A laboratory manual.- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
Messing, J. (1983) Methods Enzymol. 101, 20-78
Norrander, J. et al. (1983) Gene 2_\, 101-106
Sanger, F. et al. (1977) Proc. Natl. Acad. Sci. USA 74, 5463-5467
Yanisch-Perron, C. (1985) Gene l_\, 103-119

Claims (7)

A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is (a) the 585 to 1578 portion of human fibronectin or a variant thereof, (b) the 1 to 368 portion of CD4 or a variant thereof, (c) platelet derived growth factor or a variant thereof, (d) transforming growth factor β or a variant thereof, (e) the 1-261 portion of mature human plasma fibronectin or a variant thereof, (f) the 278-578 portion of mature human plasma fibronectin or a variant thereof, (g) the 1-272 portion of mature human von Willebrand’s Factor or a variant thereof, or (h) alpha-1-antitrypsin or a variant thereof.

2. A fusion polypeptide according to Claim 1 additionally comprising at least one N-terminal amino acid extending beyond the portion corresponding to the N-terminal portion of HSA.

3. A fusion polypeptide according to Claim 1 or 2 wherein there is a cieavable region at the junction of the said N-terminal or C-terminal portions.

4. A fusion polypeptide according to any one of the preceding claims wherein the said C-terminal portion is the 585 to 1578 portion of human plasma fibronectin or a variant thereof.

5. A transformed or transfected host having a nucleotide sequence so arranged as to express a fusion polypeptide according to any one of the preceding claims.

6. A process for preparing a fusion polypeptide by cultivation of a host according to Claim 5, followed by separation of the fusion polypeptide in a useful
. form.

7. A fusion polypeptide according to any one of Claims 1 to 4 for use in therapy.

AU55646/90A
1989-04-29
1990-04-26
Fusion proteins containing n-terminal fragments of human serum albumin

Expired

AU630450B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

GB898909916A

GB8909916D0
(en)

1989-04-29
1989-04-29
Polypeptides

GB8909916

1989-04-29

Publications (2)

Publication Number
Publication Date

AU5564690A
true

AU5564690A
(en)

1990-11-29

AU630450B2

AU630450B2
(en)

1992-10-29

Family
ID=10656000
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU55646/90A
Expired

AU630450B2
(en)

1989-04-29
1990-04-26
Fusion proteins containing n-terminal fragments of human serum albumin

Country Status (12)

Country
Link

EP
(1)

EP0470165A1
(en)

JP
(1)

JP2781459B2
(en)

KR
(1)

KR100227167B1
(en)

AU
(1)

AU630450B2
(en)

CA
(1)

CA2015687C
(en)

FI
(1)

FI104255B
(en)

GB
(2)

GB8909916D0
(en)

HU
(1)

HUT61049A
(en)

IE
(1)

IE67651B1
(en)

IL
(1)

IL94243A
(en)

WO
(1)

WO1990013653A1
(en)

ZA
(1)

ZA903237B
(en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5610148A
(en)

1991-01-18
1997-03-11
University College London
Macroscopically oriented cell adhesion protein for wound treatment

US5629287A
(en)

1991-01-18
1997-05-13
University College London
Depot formulations

FR2686900B1
(en)

1992-01-31
1995-07-21
Rhone Poulenc Rorer Sa

NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

FR2686899B1
(en)

1992-01-31
1995-09-01
Rhone Poulenc Rorer Sa

NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

WO1994016085A2
(en)

1992-12-30
1994-07-21
Zymogenetics, Inc.
Hybrid proteins having cross-linking and tissue-binding activities

GB9408466D0
(en)

1994-04-27
1994-06-22
Univ Nottingham
Cloning and functional expression of neurotoxins

US5543308A
(en)

1994-10-18
1996-08-06
New England Biolabs, Inc.
Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same

US5877149A
(en)

1995-06-07
1999-03-02
Beaulieu; Andre
Deepithelialized skin diffusion cell system

US5641483A
(en)

1995-06-07
1997-06-24
Beaulieu; Andre
Wound healing formulations containing human plasma fibronectin

US6423512B1
(en)

1996-07-26
2002-07-23
Novartis Ag
Fusion polypeptides

PE99498A1
(en)

1996-07-26
1999-01-21
Novartis Ag

FUSION POLYPEPTIDES

US5932693A
(en)

1996-12-10
1999-08-03
Washington University
Antithrombotic peptides

KR20010034305A
(en)

1998-01-23
2001-04-25
한센 핀 베네드
Process for making desired polypeptides in yeast

EP1088084B1
(en)

1998-06-15
2006-09-13
GTC Biotherapeutics, Inc.
Erythropoietin analog-human serum albumin fusion protein

EP2267026A1
(en)

2000-04-12
2010-12-29
Human Genome Sciences, Inc.
Albumin fusion proteins

CN100510060C
(en)

2001-08-15
2009-07-08
宝生物工程株式会社
Method of extended culture for antigen-specific cytotoxic t lymphocytes

EP2261250B1
(en)

2001-12-21
2015-07-01
Human Genome Sciences, Inc.
GCSF-Albumin fusion proteins

CN100591760C
(en)

2002-03-25
2010-02-24
宝生物工程株式会社
Process for producing cytotoxic lymphocyte

US8927273B2
(en)

2003-08-22
2015-01-06
Takara Bio Inc.
Process for producing cytotoxic lymphocytes

DK2520654T3
(en)

2003-08-26
2017-05-01
Univ Colorado Regents

Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections

GB0329722D0
(en)

2003-12-23
2004-01-28
Delta Biotechnology Ltd
Modified plasmid and use thereof

GB0329681D0
(en)

2003-12-23
2004-01-28
Delta Biotechnology Ltd
Gene expression technique

DK2330200T3
(en)

2004-12-23
2017-07-24
Albumedix As

GENE EXPRESSION TECHNIQUE

EP1816201A1
(en)

2006-02-06
2007-08-08
CSL Behring GmbH
Modified coagulation factor VIIa with extended half-life

WO2007146038A2
(en)

2006-06-07
2007-12-21
Human Genome Sciences, Inc.
Albumin fusion proteins

AU2007274035A1
(en)

2006-07-13
2008-01-17
Novozymes Biopharma Dk A/S
Process for preparing particles of proteinaceous material

WO2010092135A2
(en)

2009-02-11
2010-08-19
Novozymes Biopharma Uk Ltd.
Albumin variants and conjugates

US8748380B2
(en)

2009-10-30
2014-06-10
Novozymes Biopharma Dk A/S
Albumin variants

KR20130070576A
(en)

2010-04-09
2013-06-27
노보자임스 바이오파마 디케이 에이/에스
Albumin derivatives and variants

EP3628327A1
(en)

2011-06-24
2020-04-01
The Regents of the University of Colorado, A Body Corporate
Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

WO2013075066A2
(en)

2011-11-18
2013-05-23
Eleven Biotherapeutics, Inc.
Proteins with improved half-life and other properties

PL2825556T3
(en)

2012-03-16
2018-10-31
Albumedix A/S
Albumin variants

KR20150082422A
(en)

2012-11-08
2015-07-15
노보자임스 바이오파마 디케이 에이/에스
Albumin variants

WO2014165093A2
(en)

2013-03-13
2014-10-09
Bristol-Myers Squibb Company
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto

CN108137674B
(en)

2015-08-20
2022-12-06
阿尔布梅迪克斯医疗有限公司
Albumin variants and conjugates

EP3538560A4
(en)

2016-11-10
2020-06-17
Keros Therapeutics, Inc.
Gdnf fusion polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

SE459586B
(en)

1987-09-14
1989-07-17
Mta Szegedi Biolog Koezponti

THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION

GB8725529D0
(en)

1987-10-30
1987-12-02
Delta Biotechnology Ltd
Polypeptides

1989

1989-04-29
GB
GB898909916A
patent/GB8909916D0/en
active
Pending

1990

1990-04-26
WO
PCT/GB1990/000650
patent/WO1990013653A1/en
active
IP Right Grant

1990-04-26
HU
HU904413A
patent/HUT61049A/en
unknown

1990-04-26
AU
AU55646/90A
patent/AU630450B2/en
not_active
Expired

1990-04-26
EP
EP90907285A
patent/EP0470165A1/en
active
Pending

1990-04-26
JP
JP2506978A
patent/JP2781459B2/en
not_active
Expired – Lifetime

1990-04-27
IE
IE155490A
patent/IE67651B1/en
not_active
IP Right Cessation

1990-04-27
ZA
ZA903237A
patent/ZA903237B/en
unknown

1990-04-27
CA
CA002015687A
patent/CA2015687C/en
not_active
Expired – Lifetime

1990-04-29
IL
IL9424390A
patent/IL94243A/en
not_active
IP Right Cessation

1991

1991-09-06
GB
GB9119043A
patent/GB2246783B/en
not_active
Expired – Lifetime

1991-10-14
KR
KR1019910701334A
patent/KR100227167B1/en
not_active
IP Right Cessation

1991-10-28
FI
FI915073A
patent/FI104255B/en
active

Also Published As

Publication number
Publication date

IL94243A
(en)

1995-10-31

FI915073A0
(en)

1991-10-28

FI104255B1
(en)

1999-12-15

GB2246783A
(en)

1992-02-12

GB2246783B
(en)

1992-10-14

ZA903237B
(en)

1991-03-27

JP2781459B2
(en)

1998-07-30

KR100227167B1
(en)

1999-10-15

FI104255B
(en)

1999-12-15

GB8909916D0
(en)

1989-06-14

HU904413D0
(en)

1992-01-28

AU630450B2
(en)

1992-10-29

CA2015687C
(en)

2000-08-29

KR920701451A
(en)

1992-08-11

IE67651B1
(en)

1996-04-17

IL94243A0
(en)

1991-01-31

WO1990013653A1
(en)

1990-11-15

IE901554L
(en)

1990-10-29

CA2015687A1
(en)

1990-10-29

EP0470165A1
(en)

1992-02-12

GB9119043D0
(en)

1991-12-04

HUT61049A
(en)

1992-11-30

JPH04506598A
(en)

1992-11-19

Contact information